Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

GNAI1 and GNAI3 Reduce Colitis-Associated Tumorigenesis in Mice by Blocking IL6 Signaling and Down-regulating Expression of GNAI2.

Li ZW, Sun B, Gong T, Guo S, Zhang J, Wang J, Sugawara A, Jiang M, Yan J, Gurary A, Zheng X, Gao B, Xiao SY, Chen W, Ma C, Farrar C, Zhu C, Chan OTM, Xin C, Winnicki A, Winnicki J, Tang M, Park R, Winnicki M, Diener K, Wang Z, Liu Q, Chu CH, Arter ZL, Yue P, Alpert L, Hui GS, Fei P, Turkson J, Yang W, Wu G, Tao A, Ramos JW, Moisyadi S, Holcombe RF, Jia W, Birnbaumer L, Zhou X, Chu WM.

Gastroenterology. 2019 Jun;156(8):2297-2312. doi: 10.1053/j.gastro.2019.02.040. Epub 2019 Mar 2.

PMID:
30836096
2.

Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer.

Elie BT, Fernández-Gallardo J, Curado N, Cornejo MA, Ramos JW, Contel M.

Eur J Med Chem. 2019 Jan 1;161:310-322. doi: 10.1016/j.ejmech.2018.10.034. Epub 2018 Oct 17.

PMID:
30368130
3.

RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases.

Shi GX, Yang WS, Jin L, Matter ML, Ramos JW.

Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):E190-E199. doi: 10.1073/pnas.1708584115. Epub 2017 Dec 26.

4.

PEA-15 (Phosphoprotein Enriched in Astrocytes 15) Is a Protective Mediator in the Vasculature and Is Regulated During Neointimal Hyperplasia.

Greig FH, Kennedy S, Gibson G, Ramos JW, Nixon GF.

J Am Heart Assoc. 2017 Sep 11;6(9). pii: e006936. doi: 10.1161/JAHA.117.006936.

5.

PTRH2 gene mutation causes progressive congenital skeletal muscle pathology.

Doe J, Kaindl AM, Jijiwa M, de la Vega M, Hu H, Griffiths GS, Fontelonga TM, Barraza P, Cruz V, Van Ry P, Ramos JW, Burkin DJ, Matter ML.

Hum Mol Genet. 2017 Apr 15;26(8):1458-1464. doi: 10.1093/hmg/ddx048.

6.

RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.

Sulzmaier FJ, Young-Robbins S, Jiang P, Geerts D, Prechtl AM, Matter ML, Kesari S, Ramos JW.

Oncotarget. 2016 Nov 29;7(48):79869-79884. doi: 10.18632/oncotarget.13084.

7.

Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer.

Jorand R, Biswas S, Wakefield DL, Tobin SJ, Golfetto O, Hilton K, Ko M, Ramos JW, Small AR, Chu P, Singh G, Jovanovic-Talisman T.

Mol Biol Cell. 2016 Nov 7;27(22):3659-3672. Epub 2016 Sep 28.

8.

Heterometallic titanium-gold complexes inhibit renal cancer cells in vitro and in vivo.

Fernández-Gallardo J, Elie BT, Sadhukha T, Prabha S, Sanaú M, Rotenberg SA, Ramos JW, Contel M.

Chem Sci. 2015 Sep 1;6(9):5269-5283. doi: 10.1039/C5SC01753J. Epub 2015 Jun 23.

9.

Synthesis of a stable and orally bioavailable englerin analogue.

Fash DM, Peer CJ, Li Z, Talisman IJ, Hayavi S, Sulzmaier FJ, Ramos JW, Sourbier C, Neckers L, Figg WD, Beutler JA, Chain WJ.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2641-4. doi: 10.1016/j.bmcl.2016.04.016. Epub 2016 Apr 8.

10.

Bit-1 is an essential regulator of myogenic differentiation.

Griffiths GS, Doe J, Jijiwa M, Van Ry P, Cruz V, de la Vega M, Ramos JW, Burkin DJ, Matter ML.

J Cell Sci. 2015 May 1;128(9):1707-17. doi: 10.1242/jcs.158964. Epub 2015 Mar 13.

11.

Neopetrocyclamines A and B, polycyclic diamine alkaloids from the sponge Neopetrosia cf exigua.

Liang Z, Sulzmaier FJ, Yoshida WY, Kelly M, Ramos JW, Williams PG.

J Nat Prod. 2015 Mar 27;78(3):543-7. doi: 10.1021/np500759r. Epub 2015 Jan 13.

12.

Organometallic Titanocene-Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties.

Fernández-Gallardo J, Elie BT, Sulzmaier FJ, Sanaú M, Ramos JW, Contel M.

Organometallics. 2014 Nov 24;33(22):6669-6681. Epub 2014 Oct 30.

13.

In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer.

Frik M, Martínez A, Elie BT, Gonzalo O, Ramírez de Mingo D, Sanaú M, Sánchez-Delgado R, Sadhukha T, Prabha S, Ramos JW, Marzo I, Contel M.

J Med Chem. 2014 Dec 11;57(23):9995-10012. doi: 10.1021/jm5012337. Epub 2014 Nov 26.

14.

Suggested modification of the technique coronectomy for lower third molar.

Rocha JF, de Oliveira JC, Ramos JW, Garcia Júnior IR, Hochuli-Vieira E.

J Craniofac Surg. 2014 Nov;25(6):2264-6. doi: 10.1097/SCS.0000000000001154S. No abstract available.

PMID:
25377977
15.

Targeted deletion of RasGRP1 impairs skin tumorigenesis.

Sharma A, Fonseca LL, Rajani C, Yanagida JK, Endo Y, Cline JM, Stone JC, Ji J, Ramos JW, Lorenzo PS.

Carcinogenesis. 2014 May;35(5):1084-91. doi: 10.1093/carcin/bgu016. Epub 2014 Jan 24.

16.

RSK isoforms in cancer cell invasion and metastasis.

Sulzmaier FJ, Ramos JW.

Cancer Res. 2013 Oct 15;73(20):6099-105. doi: 10.1158/0008-5472.CAN-13-1087. Epub 2013 Oct 4. Review.

17.

Englerin a selectively induces necrosis in human renal cancer cells.

Sulzmaier FJ, Li Z, Nakashige ML, Fash DM, Chain WJ, Ramos JW.

PLoS One. 2012;7(10):e48032. doi: 10.1371/journal.pone.0048032. Epub 2012 Oct 22.

18.

RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration.

Gawecka JE, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Heikkilä MM, Matter ML, Ramos JW.

J Biol Chem. 2012 Dec 21;287(52):43424-37. doi: 10.1074/jbc.M112.423046. Epub 2012 Nov 1.

19.

Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter.

Sulzmaier F, Opoku-Ansah J, Ramos JW.

Small GTPases. 2012 Jul-Sep;3(3):173-7. doi: 10.4161/sgtp.20021. Epub 2012 Jun 14.

20.

PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.

Gawecka JE, Geerts D, Koster J, Caliva MJ, Sulzmaier FJ, Opoku-Ansah J, Wada RK, Bachmann AS, Ramos JW.

Int J Cancer. 2012 Oct 1;131(7):1556-68. doi: 10.1002/ijc.27415. Epub 2012 Jan 31.

21.

PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D.

Sulzmaier FJ, Valmiki MK, Nelson DA, Caliva MJ, Geerts D, Matter ML, White EP, Ramos JW.

Oncogene. 2012 Jul 26;31(30):3547-60. doi: 10.1038/onc.2011.514. Epub 2011 Nov 21.

22.

Stictamides A-C, MMP12 inhibitors containing 4-amino-3-hydroxy-5-phenylpentanoic acid subunits.

Liang Z, Sorribas A, Sulzmaier FJ, Jiménez JI, Wang X, Sauvage T, Yoshida WY, Wang G, Ramos JW, Williams PG.

J Org Chem. 2011 May 20;76(10):3635-43. doi: 10.1021/jo200241h. Epub 2011 Apr 18.

23.

Bit-1 mediates integrin-dependent cell survival through activation of the NFkappaB pathway.

Griffiths GS, Grundl M, Leychenko A, Reiter S, Young-Robbins SS, Sulzmaier FJ, Caliva MJ, Ramos JW, Matter ML.

J Biol Chem. 2011 Apr 22;286(16):14713-23. doi: 10.1074/jbc.M111.228387. Epub 2011 Mar 7.

24.

A phospholipase Cγ1-activated pathway regulates transcription in human vascular smooth muscle cells.

Hunter I, Mascall KS, Ramos JW, Nixon GF.

Cardiovasc Res. 2011 Jun 1;90(3):557-64. doi: 10.1093/cvr/cvr039. Epub 2011 Feb 1.

25.

R-Ras regulates migration through an interaction with filamin A in melanoma cells.

Gawecka JE, Griffiths GS, Ek-Rylander B, Ramos JW, Matter ML.

PLoS One. 2010 Jun 23;5(6):e11269. doi: 10.1371/journal.pone.0011269.

26.

The death effector domain protein PEA-15 negatively regulates T-cell receptor signaling.

Pastorino S, Renganathan H, Caliva MJ, Filbert EL, Opoku-Ansah J, Sulzmaier FJ, Gawecka JE, Werlen G, Shaw AS, Ramos JW.

FASEB J. 2010 Aug;24(8):2818-28. doi: 10.1096/fj.09-144295. Epub 2010 Mar 30.

27.

Deletion of PEA-15 in mice is associated with specific impairments of spatial learning abilities.

Ramos JW, Townsend DA, Piarulli D, Kolata S, Light K, Hale G, Matzel LD.

BMC Neurosci. 2009 Nov 16;10:134. doi: 10.1186/1471-2202-10-134.

28.

Death effector domain-containing proteins.

Valmiki MG, Ramos JW.

Cell Mol Life Sci. 2009 Mar;66(5):814-30. doi: 10.1007/s00018-008-8489-0. Review.

PMID:
18989622
29.

The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells.

Ramos JW.

Int J Biochem Cell Biol. 2008;40(12):2707-19. doi: 10.1016/j.biocel.2008.04.009. Epub 2008 May 15. Review.

PMID:
18562239
30.

Glioma: challenges and new insights in the development of effective therapies.

Pastorino S, Ramos JW.

Hawaii Med J. 2008 Jan;67(1):20-3, 25. Review. No abstract available.

PMID:
18309836
31.

ERK MAP kinase is targeted to RSK2 by the phosphoprotein PEA-15.

Vaidyanathan H, Opoku-Ansah J, Pastorino S, Renganathan H, Matter ML, Ramos JW.

Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19837-42. Epub 2007 Dec 6.

32.

Phosphoprotein enriched in astrocytes-15 kDa expression inhibits astrocyte migration by a protein kinase C delta-dependent mechanism.

Renault-Mihara F, Beuvon F, Iturrioz X, Canton B, De Bouard S, Léonard N, Mouhamad S, Sharif A, Ramos JW, Junier MP, Chneiweiss H.

Mol Biol Cell. 2006 Dec;17(12):5141-52. Epub 2006 Sep 20.

33.

Expression cloning of signaling proteins regulated by cell adhesion.

Matter ML, Ramos JW.

Methods Mol Biol. 2006;341:155-65. Review.

PMID:
16799197
34.

Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD.

Renganathan H, Vaidyanathan H, Knapinska A, Ramos JW.

Biochem J. 2005 Sep 15;390(Pt 3):729-35.

35.

Cancer research center hotline: PEA-15 phosphoprotein: a potential cancer drug target.

Ramos JW.

Hawaii Med J. 2005 Mar;64(3):77-80. No abstract available.

PMID:
15892267
36.
37.

PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation.

Chou FL, Hill JM, Hsieh JC, Pouyssegur J, Brunet A, Glading A, Uberall F, Ramos JW, Werner MH, Ginsberg MH.

J Biol Chem. 2003 Dec 26;278(52):52587-97. Epub 2003 Sep 23.

38.

RSK2 activity is regulated by its interaction with PEA-15.

Vaidyanathan H, Ramos JW.

J Biol Chem. 2003 Aug 22;278(34):32367-72. Epub 2003 Jun 9.

39.

Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain.

Hill JM, Vaidyanathan H, Ramos JW, Ginsberg MH, Werner MH.

EMBO J. 2002 Dec 2;21(23):6494-504.

40.

Expression cloning strategies for the identification of adhesion molecules.

Ramos JW, Ginsberg M.

Methods Cell Biol. 2002;69:209-21. No abstract available.

PMID:
12070994
41.

PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase.

Formstecher E, Ramos JW, Fauquet M, Calderwood DA, Hsieh JC, Canton B, Nguyen XT, Barnier JV, Camonis J, Ginsberg MH, Chneiweiss H.

Dev Cell. 2001 Aug;1(2):239-50.

42.

Identification of cell signaling molecules by expression cloning.

Matter ML, Ginsberg MH, Ramos JW.

Sci STKE. 2001 Oct 9;2001(103):pl9.

PMID:
11593050
43.

Death effector domain protein PEA-15 potentiates Ras activation of extracellular signal receptor-activated kinase by an adhesion-independent mechanism.

Ramos JW, Hughes PE, Renshaw MW, Schwartz MA, Formstecher E, Chneiweiss H, Ginsberg MH.

Mol Biol Cell. 2000 Sep;11(9):2863-72.

44.

The death effector domain of PEA-15 is involved in its regulation of integrin activation.

Ramos JW, Kojima TK, Hughes PE, Fenczik CA, Ginsberg MH.

J Biol Chem. 1998 Dec 18;273(51):33897-900.

45.

Complementation of dominant suppression implicates CD98 in integrin activation.

Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH.

Nature. 1997 Nov 6;390(6655):81-5.

PMID:
9363894
46.

Integrin-dependent adhesive activity is spatially controlled by inductive signals at gastrulation.

Ramos JW, Whittaker CA, DeSimone DW.

Development. 1996 Sep;122(9):2873-83.

Supplemental Content

Loading ...
Support Center